BioSpace News Archive

Baxter International Inc. announced today the introduction of three scholarship and grant programs to support Black students pursuing health and science degrees and ultimately help expand the pipeline of Black healthcare professionals.

Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease.

POC devices or point of care devices are mainly used for medical diagnostic tests. These tests are conducted at a time and place convenient for patient care.

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence.

Celularity today announced expansion of its ongoing Phase 1 clinical trial of CYNK-001 in AML (NCT04310592) to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in patients with MRD.

Lyfebulb, and Arena Pharmaceuticals, a company focused on developing innovative therapeutics for immune-mediated conditions, announce the ten patient entrepreneurs selected as finalists for the 2021 Imagining Life Without Limits – An Inflammatory Bowel Disease Innovation Challenge.

SwanBio Therapeutics today announced the initiation of the CYGNET study with the enrollment of the first two participants.

MediWound Ltd. today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking approval of NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.

Nihon Kohden America, a U.S. market leader in precision medical products and services, realizes over the past year, the pandemic has generated many changes and challenges within the medical industry.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the initiation of the DEFINE AFib study, the company’s first app-based research study.